Login to Your Account

Blisibimod prospects look brighter as data mature

By Marie Powers
News Editor

Wednesday, December 7, 2016

One month after shares of Anthera Pharmaceuticals Inc. took a 30 percent haircut following a phase III miss by blisibimod in SLE, investors did an about-face on maturing data from the phase BRIGHT-SC proof-of-concept study of the same agent.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription